For scientists working to develop Alzheimer’s treatments, knowing what is already being tested can help reveal where to go next.
Dr. Jeffrey Cummings and his team at the Kirk Kerkorian School of Medicine at UNLV have spent years assembling that picture. Now, a partnership will give researchers around the world new ways to use it.
Data from UNLV’s Clinical Trials Observatory is now available through the AD Workbench, the secure, cloud-based research platform of the Alzheimer’s Disease Data Initiative. The collaboration will let scientists explore the observatory’s information alongside other datasets, potentially helping them make more informed decisions about new clinical trials.
“This is part of open science that allows our UNLV-sourced data to become part of the universe of information that will drive Alzheimer’s disease understanding and therapeutics ahead,” Cummings says. “We are very excited about this.”
For UNLV and the medical school, the partnership strengthens their position as worldwide leaders in Alzheimer’s research. Work developed at the school will become a resource that scientists across institutions can use to guide their own investigations.
“This is important because the AD Workbench has access to many other types of data,” Cummings says.
A Clearer Picture of the Pipeline
The observatory is the world’s only research observatory dedicated exclusively to analyzing the pipeline of Alzheimer’s drugs in clinical trials. It tracks experimental treatments as they move through testing, helping researchers understand the approaches under study, and the gaps that remain.
Drawing on registrations in ClinicalTrials.gov, the observatory organizes information across more than 20 fields and updates it daily. Its value comes from turning those records into a detailed, current picture of drug development.
“The observatory gives the field a shared, current picture of what is being tested and why,” says Niranjan Bose, interim executive director of the Alzheimer’s Disease Data Initiative.
Bose says the resource builds on Cummings’ drug development pipeline work over the past decade. Bringing it to the AD Workbench will allow researchers to combine trial information with other datasets and analyze it within a secure environment.
“This helps turn observatory data from a reference resource into an input for analysis,” Bose says.
That could mean identifying treatment targets with relatively few drugs in development or populations receiving less attention in clinical trials. Researchers could also compare how trials measure success, how long they run, and how they use biomarkers, biological indicators that help researchers assess disease or a treatment’s effects.
Examining the observatory’s information alongside findings from animal studies or chemical research could give scientists a broader foundation for planning their next study.
Connecting Researchers Around the World
AD Workbench is free to users and provides secure cloud-based workspaces where researchers from different institutions can collaborate. According to Bose, its community includes more than 11,000 people working on Alzheimer’s and related dementia research, and more than 380 datasets are available to request through the platform.
That reach gives UNLV’s work an opportunity to inform projects far beyond the university. A research team could use the observatory to examine gaps in the treatment pipeline, then draw on other datasets to help investigate an approach that might address them.
The partnership also supports the AD Data Initiative’s mission of making data, tools, and findings easier to share so researchers worldwide can work together to accelerate discovery.
Artificial intelligence will play a role, with additional capabilities still in development. Bose says the AD Data Initiative’s roadmap includes 19 AI tools, five of which are currently available. The tools are intended to help researchers find datasets, request access, and analyze information.
The organization has also begun working with Cummings on an AI analysis layer for the observatory database. Bose describes that effort as a work in progress.
Building on a Career of Discovery
Cummings announced the collaboration at the Clinical Trials on Alzheimer’s Disease conference in Boston, where he received the Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research.
The award recognizes his contributions to clinical trial methods and drug development frameworks, along with his years of leadership through annual analyses of the Alzheimer’s drug pipeline.
Cummings is the Joy Chambers-Grundy professor of brain science and directs the Chambers-Grundy Center for Transformative Neuroscience in the medical school’s department of brain health. He joined UNLV in 2019 after serving as founding director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas.
In 2024, ScholarGPS ranked him as the world’s top scholar for lifetime contributions in dementia and drug development.
The collaboration gives that expertise a wider reach, connecting the observatory’s work at UNLV with scientists pursuing new approaches to Alzheimer’s treatment around the world.
Want to stay updated and learn more about the medical school?
Subscribe to the Kirk Kerkorian School of Medicine at UNLV Making the Rounds newsletter to stay updated on the school’s progress in transforming healthcare in Southern Nevada!